Literature DB >> 25218469

Down-regulation of ether-a-go-go-related gene potassium channel protein through sustained stimulation of AT1 receptor by angiotensin II.

Yue Cai1, Yuhong Wang1, Jia Xu1, Xu Zuo1, Yanfang Xu2.   

Abstract

We investigated the effects of AT1 receptor stimulation by angiotensin II (Ang II) on human ether-a-go-go-related gene (hERG) potassium channel protein in a heterogeneous expression system with the human embryonic kidney (HEK) 293 cells which stably expressed hERG channel protein and were transiently transfected with the human AT1 receptors (HEK293/hERG). Western-blot analysis showed that Ang II significantly decreased the expression of mature hERG channel protein (155-kDa band) in a time- and dose-dependent manner without affecting the level of immature hERG channel protein (135-kDa band). The relative intensity of 155-kDa band was 64.7±6.8% of control (P<0.01) after treatment of Ang II at 100nM for 24h. To investigate the effect of Ang II on the degradation of mature hERG channel protein, we blocked forward trafficking from ER to Golgi with a Golgi transit inhibitor brefeldin A (10μM). Ang II significantly enhanced the time-dependent reduction of mature hERG channel protein. In addition, the proteasomal inhibitor lactacystin (5μM) inhibited Ang II-mediated the reduction of mature hERG channel protein, but the lysosomal inhibitor bafilomycin A1 (1μM) had no effect on the protein. The protein kinase C (PKC) inhibitor bisindolylmaleimide 1 (1μM) antagonized the reduction of mature hERG channel protein induced by Ang II. The results indicate that sustained stimulation of AT1 receptors by Ang II reduces the mature hERG channel protein via accelerating channel proteasomal degradation involving the PKC pathway.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AT(1) receptor; Protein degradation; Protein kinase C; hERG channel protein

Mesh:

Substances:

Year:  2014        PMID: 25218469     DOI: 10.1016/j.bbrc.2014.09.014

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Different protein kinase C isoenzymes mediate inhibition of cardiac rapidly activating delayed rectifier K+ current by different G-protein coupled receptors.

Authors:  Xueli Liu; Yuhong Wang; Hua Zhang; Li Shen; Yanfang Xu
Journal:  Br J Pharmacol       Date:  2017-11-07       Impact factor: 8.739

2.  Angiotensin II Promotes KV7.4 Channels Degradation Through Reduced Interaction With HSP90 (Heat Shock Protein 90).

Authors:  Vincenzo Barrese; Jennifer B Stott; Hericka B Figueiredo; Aisah A Aubdool; Adrian J Hobbs; Thomas A Jepps; Alister J McNeish; Iain A Greenwood
Journal:  Hypertension       Date:  2018-04-23       Impact factor: 10.190

3.  Angiopoietin-like protein 2 expression is suppressed by angiotensin II via the angiotensin II type 1 receptor in rat cardiomyocytes.

Authors:  Shuya Wang; Ying Li; Wei Miao; Hong Zhao; Feng Zhang; Nan Liu; Guohai Su; Xiaojun Cai
Journal:  Mol Med Rep       Date:  2016-07-25       Impact factor: 2.952

4.  Arsenic trioxide and angiotensin II have inhibitory effects on HERG protein expression: Evidence for the role of PML SUMOylation.

Authors:  Yu Liu; Duo Li; Dan Nie; Shang-Kun Liu; Fang Qiu; Mei-Tong Liu; Yuan-Yuan Li; Jia-Xin Wang; Yan-Xin Liu; Chang-Jiang Dong; Di Wu; Wei Tian; Jia Yang; Wei Mu; Jia-Tong Li; Dan Zhao; Xiao-Feng Wang; Wen-Feng Chu; Bao-Feng Yang
Journal:  Oncotarget       Date:  2017-07-11

5.  Synergistic interplay of Gβγ and phosphatidylinositol 4,5-bisphosphate dictates Kv7.4 channel activity.

Authors:  Oleksandr V Povstyan; Vincenzo Barrese; Jennifer B Stott; Iain A Greenwood
Journal:  Pflugers Arch       Date:  2016-12-15       Impact factor: 3.657

6.  Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy.

Authors:  Hua Zhang; Tian Fu; Jinglei Sun; Sihao Zou; Suhua Qiu; Jiali Zhang; Shi Su; Chenxia Shi; De-Pei Li; Yanfang Xu
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.